A Silent Emergency in Modern Medicine 

In 2019, an estimated 2.8 million antimicrobial-resistant (AMR) infections were documented across the United States. In the same year, antimicrobial-resistant infections contributed to approximately 35,000 deaths annually, according to the Centers for Disease Control and Prevention (CDC). The numbers are outstanding, yet public awareness of AMR remains scarce. In addition to this, adverse drug reactions (ADRs) are estimated to contribute to over 100,000 hospitalizations a year in the United States.

These statistics highlight intersecting emergencies. Despite medical advancements, U.S. drug safety monitoring remains fragmented and strained. The uprising of AMR and ADRs draws attention to a larger concern: current U.S. pharmacovigilance is struggling to keep up with how fast pharmaceutical and microbial risks are changing. 

Reactive Monitoring 

Pharmacovigilance in the United States emerged in response to significant drug safety failures, most remarkably the thalidomide crisis of the 1960s. This crisis, which led to severe birth defects globally, including 17 documented cases in the United States, prompted legislative action. As a result, the Kefauver-Harris Amendments of 1962 were enacted, which strengthened drug regulation and safety monitoring. These amendments required drug manufacturers to provide evidence that their products are safe and effective before receiving approval to release them on the market, mandated clinical trials with informed patient consent, and enhanced post-market drug surveillance to assess and monitor ADRs.

The FDA’s Response

Over time, institutions have implemented post-market drug monitoring systems like the Adverse Event Reporting System (FAERS) and the National Antimicrobial Resistance Monitoring System (NARMS) to safeguard public health. Both were developed by the Food and Drug Administration (FDA). However, these systems depend on voluntary data reporting, which often results in the under-reporting of safety data and the underestimation of harm. 

The U.S. currently has separate surveillance infrastructure for ADRs and AMR despite their intersection. Antibiotics are most frequently associated with ADR cases, which result in incomplete treatment and thus encourage the adaptation and resistance of bacteria. These two programs, one tracking ADR and the other monitoring AMR, are disjointed and lack integration between the monitoring of adverse human reactions to medication and the microbial responses to antibiotic use. 

Modern Handling of U.S. Drug Safety

The United States primarily uses the FAERS database to report ADR cases. FAERS collects reports of ADRs from healthcare providers, manufacturers, and patients, helping to detect early safety concerns and evaluate the risk profiles of medications. However, it only captures a fraction of adverse events due to the system’s reliance on voluntary reporting. The FDA indicates that less than 10% of ADRs are reported to their systems. 

The NARMS database directly monitors resistance trends in foodborne bacteria across humans, animals, and retail meat. The federal oversight of AMR is allocated to agencies such as the FDA, CDC, and USDA; these institutions all operate independently with different sectors of interest, protocols, and databases. However, NARMS is managed independently from medical treatment reports. This under-coordinated effort limits the real-time utilization of AMR data in clinical decision-making/workflows and undermines the detection of emerging resistance trends.

Gaps in Pharmacovigilance 

Fragmented systems and inconsistent reporting have real-world implications. For example, when ADRs are under-reported, it delays timely regulatory responses such as product recalls or boxed warnings, which increases the risk of patient harm. A notable case of this was the delayed withdrawal of an anti-inflammatory painkiller, Vioxx (rofecoxib), which was associated with an increased risk of heart attack and stroke. Despite emerging safety concerns, the drug remained on the market for five years. Vioxx contributed to up to 140,000 cases of serious heart conditions in the U.S. before it was removed from the market in 2004.

Antibiotics

Antibiotics, one of the most frequently implicated drug classes that result in ADR cases, present another pressing concern. Inappropriate antibiotic prescriptions, often driven by diagnostic uncertainty, patient pressure, and insufficient provider support, continue to accelerate resistance trends. For example, antibiotics are commonly prescribed for viral illnesses such as the common cold, despite providing no benefit. Patients experiencing side effects, like allergic reactions or gastrointestinal issues, from antibiotics may prematurely end their treatment, which not only undermines the treatment’s effectiveness but also promotes the growth of resistant bacteria.

These challenges are further complicated when federal agencies like the FDA, CDC, and USDA do not communicate or coordinate effectively. When communication between agencies is poor, the speed and accuracy of resistance surveillance can be compromised, posing challenges in hospital settings where quick decision-making is critical.

A Case Study from Denmark

As pharmaceutical innovations continue to evolve, new challenges are presented to the U.S. monitoring systems for drug safety and effectiveness. Traditional approaches that address AMR and ADRs separately have shown limitations in managing these interconnected issues.

Other countries have begun to address the rising cases of antibiotic resistance through integrated approaches. Denmark’s DANMAP program, for instance, unites AMR data from humans, animals, and food into a single national platform, enabling a faster, more coordinated response to emerging threats. There is growing demand for the United States to adopt similar models, systems that integrate digital tools, align human and veterinary health, and treat pharmacovigilance as the groundwork of national health security. In Denmark’s case, the integrated surveillance system strengthens responses to existing drug safety issues and ensures resilience against emerging future threats. There is growing potential for the U.S. to follow suit by exploring similar models that enhance coordination across human and veterinary health sectors and use advanced digital systems.

New Approaches

Several developments are cause for optimism regarding pharmacovigilance in the United States. Recent federal initiatives aim to enhance data integration and strengthen antibiotic stewardship programs nationwide. Advancements in digital health tools and machine learning allow for real-time signal detections. Meanwhile, collaborations like the National Action Plan for Combating Antibiotic-Resistant Bacteria encourage coordinated efforts to improve appropriate antibiotic prescriptions and surveillance. Public awareness campaigns are on the rise, informing patients of the importance of completing antibiotic treatment plans, and recognizing adverse drug reactions early. All of these developments reflect the importance of unified action to address drug safety threats.